Development and Validation of a Physiologically Based Pharmacokinetic Model for Riociguat and Its Active Metabolite M1
This study developed and validated a robust physiologically based pharmacokinetic (PBPK) model for riociguat and its active metabolite M1 that accurately predicts complex pharmacokinetic behaviors, including enterohepatic circulation, food effects, hepatic impairment, and drug-drug interactions, thereby supporting clinical dose optimization and risk assessment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Medicines are rarely simple travelers in the human body. Once swallowed, a drug must navigate a complex landscape of organs, fluids, and biological barriers before it can do its work and eventually leave the system. For some medications, this journey is straightforward, but for others, the path is winding and unpredictable. One such medication is riociguat, a drug used to treat pulmonary hypertension, a serious condition where the blood vessels in the lungs become narrowed and stiff, forcing the heart to work much harder than it should. Because the body handles this drug in a complicated way—absorbing it, breaking it down, and then sometimes recycling parts of it back into the bloodstream—doctors face a challenge: knowing exactly how much of the drug is present at any given time to ensure it is safe and effective. This uncertainty becomes even greater when a patient has other health issues, such as liver disease, or is taking other medications that might interfere with the process.
To solve this puzzle, a team of researchers at Shenyang Pharmaceutical University built a detailed digital map of how riociguat moves through the body. Instead of relying on simple averages, they created a physiologically based pharmacokinetic model, which is essentially a computer simulation that mimics the actual human body. This virtual system includes the specific sizes of organs, the speed of blood flow, and the chemical properties of the drug itself. The researchers fed this model with data from seven different clinical studies involving healthy volunteers who took doses ranging from 0.5 to 2.5 milligrams. They also accounted for a unique quirk of this drug: enterohepatic circulation. This is a process where the liver sends the drug into the intestines via bile, and the intestines then reabsorb some of it, sending it back into the blood. This recycling loop can cause the drug levels to rise and fall in a way that standard models often miss, creating a "double peak" in the blood concentration that the researchers needed to capture accurately.
The team tested their digital map by comparing its predictions against real-world data that the model had never seen before. They found that the simulation was remarkably accurate, with more than 90 percent of its predictions falling within a safe margin of error compared to what actually happened in the patients. The model successfully explained why the drug behaves differently when taken with food. When volunteers ate a high-fat meal before taking the pill, the simulation correctly predicted that the peak amount of drug in the blood would drop to about half of what it was on an empty stomach, and that the time it took to reach that peak would stretch from just over an hour to more than three hours. This matched the clinical reports perfectly, confirming that the model understood how food slows down the drug's entry into the system.
Beyond healthy volunteers, the researchers used their model to look at what happens in people with liver problems, a common concern for patients with pulmonary hypertension. Since the liver is a primary site for breaking down riociguat, damage to this organ can cause the drug to build up to dangerous levels. The simulation created virtual populations of patients with mild and moderate liver impairment. It predicted that in those with mild impairment, the total exposure to the drug would increase by about 23 percent, while in those with moderate impairment, the increase would be roughly 35 percent. These findings suggest that doctors may need to adjust the dosage for patients with liver issues to prevent the drug from accumulating too much in their bodies.
The study also explored how riociguat interacts with other common medications. The researchers simulated scenarios where patients took the drug alongside clarithromycin, an antibiotic, and rifampicin, a treatment for tuberculosis. The model predicted that the antibiotic would cause the drug levels to rise by about 37 percent, a figure that closely matched a known clinical study result of 41 percent. Conversely, the simulation showed that rifampicin would cause the drug levels to plummet, reducing the total exposure by nearly 86 percent. This dramatic drop suggests that taking these two drugs together could make the treatment for pulmonary hypertension ineffective. By mapping these interactions without needing to run new, risky clinical trials on every possible combination, the researchers provided a clear, mechanistic understanding of how riociguat behaves. Their work offers a reliable tool for doctors to make safer, more informed decisions about dosing, ensuring that patients receive the right amount of medication whether they are healthy, have liver disease, or are taking other medicines.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.